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MyoblastMyotonic dystrophy is a neuromuscular disease of RNA toxicity. The disease gene DMPK harbors expanded CTG
trinucleotide repeats on its 3′-UTR. The transcripts of this mutant DMPK led to misregulation of RNA-binding
proteins including MBNL1 and Celf1. In myoblasts, CUG-expansion impaired terminal differentiation. In this
study, we formally tested how the abundance of Celf1 regulates normal myocyte differentiation, and how
Celf1 expression level mediates CUG-expansion RNA toxicity-triggered impairment of myocyte differentiation.
As the results, overexpression of Celf1 largely recapitulated the defects of myocytes with CUG-expansion, by in-
creasing myocyte cycling. Knockdown of endogenous Celf1 level led to precocious myotube formation, supporting
a negative connection between Celf1 abundance andmyocyte terminal differentiation. Finally, knockdown of Celf1
in myocyte with CUG-expansion led to partial rescue, by promoting cell cycle exit. Our results suggest that Celf1
plays a distinctive and negative role in terminal myocyte differentiation, which partially contribute to DM1 RNA
toxicity. Targeting Celf1 may be a valid strategy in correcting DM1 muscle phenotypes, especially for congenital
cases.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Myotonic muscular dystrophy is a common multi-system disorder
that affects the skeletal and cardiac muscles. It has two types with DM1
being the more frequent and severe. In DM1, the disease gene DMPK1
harbors an expansion of CUG triplet repeats on its 3′-UTR [1,2]. Conse-
quently, RNA-binding factors (MBNL1 and Celf1) which bind to the
CUG repeats are misregulated. Both MBNL1 and Celf1 contribute to
DM1 pathogenesis. MBNL1 is sequestered by the expanded CUG repeats,
resulting in a loss of function [3], and aberrant alternative splicing of its
targets [4]. MBNL1 knockout mice developed some of the characteristics
of DM1, in particular, misregulated mRNA splicing [5]. CUG-expansion
augments Celf1, which regulates alternative splicing, RNA stability and
translation [6,7]. Heart-speciﬁc overexpression of Celf1 caused histo-
pathological and echocardiographic abnormalities, and aberrant alter-
native splicing [8]. In the skeletal muscles, overexpression of Celf1
also reproduced DM1-like features, which were associated with Celf1-
responsive alternative splicing or aberrant stability of Celf1 targetskinase; 3′-UTR, 3′-untranslated
onic dystrophy 1; FACS,ﬂuores-
;MSCV,murine stem cell virus;
inreaction;shRNA,shorthairpin
omic repeatsp21 and MEF2A [9]. While knockout of MBNL1 did not have apparent
effects, overexpression of Celf1 in either the heart or skeletal muscles
reproduced DM1-like muscle wasting phenotypes [8,10–14].
Most DM1 cases are progressive and affect adults. However, congen-
ital cases are more severe and often lead to early lethality. The copy
number of CUG triplet repeats on DMPK 3′-UTR is directly related to
age of onset and severity, with high copy number associated with con-
genital DM1 and lethality. It was shown by serial deletions that a region
on the DMPK 3′-UTR excluding the CUG-expansion was responsible for
defective terminal myocyte differentiation [15,16]. However, other
evidence supports that CUG-expansion was the culprit [17,18], through
compromising the expression of a crucialmyogenic factorMyoD, which
may explain the lack of muscle regeneration in severe DM1 cases [17].
Celf1 expression levels are directly linked to the CUG repeat copy number
in congenital DMs. When expressed as a transgene, Celf1 inhibited
myogenesis inmouse [9]. However, the role of Celf1 inmyoblast differen-
tiation toward myotube is complex in current literature. It was reported
that different trans-regulating factors occupy the promoter of Celf1 at
different differentiation stages:while they are E12, CBP and p300 inmyo-
blasts, the combination changes tomyogenin, E12 and p300 inmyotubes,
suggesting an active role of Celf1 in myotube formation [19]. Also, inter-
actions of CUGBP1with eIF2 are reduced in DM1differentiatingmyoblast
cells, and exogenous cyclin D3 rescues the DM1 myoblast differentiation
defects by promoting the CUGBP1–eIF2 complex [20,21]. Furthermore,
overexpression of CUGBP1 induced the expression of Mef2A and p21
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the defective myocyte differentiation [9].
Here, we set to study how the abundance of Celf1 regulates normal
myocyte differentiation, and how Celf1 expression level mediates
CUG-expansion RNA toxicity-triggered impairment of it. This work
may provide insight for using Celf1 as a target in promoting normal
muscle development and correcting DM1-related defective muscle
differentiation.
2. Results
2.1. 3′-UTR CUG-expansion leads to accelerated cell cycling in myoblasts
and impaired differentiation
Although DMPKmutation is responsible for DM1, the detailed mech-
anism of how DMPK mutation causes DM1 is not entirely clear. Recent
evidence supports that the 3′-UTR CUG-expansion plays a central
role in DM1 pathogenesis. At organism level, also in myoblasts, the
CUG-expansion has been shown to inhibit terminal myocyte differenti-
ation. Independent groups demonstrated that myotube formation was
severely impaired in C2C12 cells transfected with DMPK or reporter
transgene-carried 3′-UTR CTG expansions. To set up a platform for the
rest of this study, also to test the cell cycle changes of proliferating
and differentiating myoblasts harboring 3′-UTR CTG expansions, we
transfected C2C12 myoblasts with GFP-CUG5 or GFP-CUG200, which
differ only in CUG repeat number. Cells were selected for G418 resis-
tance, and survival cloneswere pooled. Using FACS, we further enriched
the GFP-positive cells and conﬁrmed that GFP ﬂuorescent signal was
present in more than 97% of cells in both groups (Supplemental
Fig. S1). The myoblasts were differentiated in a standard protocol with
serum starvation and insulin supplements. After 6 days, myotubes
were evidently formed in GFP-CUG5-transfected cells, as visualized by
alphamyosin heavy chain staining (MF20). In contrast, theywere rarely
detected in GFP-CUG200 cultures (Fig. 1A). Quantiﬁcation of threeC
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Fig. 1. CUG-expansion increases myoblast cycling and inhibits myotube formation in C2C12
GFP-CUG5 transfected cells. Myotubes were visualized by myosin heavy chain (MF-20) immun
andmyotube areas (right). (C) Expression proﬁles of Celf1, and transcription factors MyoD, My
by realtime RT-PCR. N N 3, p b 0.05. (D) Upregulation of Celf1 protein in GFP-CUG200 transfec
FACS was performed in undifferentiated myoblasts.independent experiments showed that fusion indices in GFP-CUG5
cultures often reached 38.9 ± 8.7%, but they were only 2.2 ± 0.8% in
GFP-CUG200 cultures. Similarly, myotube areas were 40.2 ± 12.0% in
GFP-CUG5 cultures but only 3.3 ± 0.8% in GFP-CUG200 cultures
(Fig. 1B). These results agree with previous reports on the effect of
CUG-expansion RNA toxicity in myocyte differentiation.
We analyzed expression of a number ofmuscle differentiation regula-
tors. Compared to CUG5, CUG200 signiﬁcantly increased the expressionof
Celf1mRNA in both proliferatingmyoblasts and at the beginning of differ-
entiation, agreeing with the frequent observation that Celf1 upregulation
is associated with CUG-expansion in DM1 (Fig. 1C). Celf1 protein level
was elevated accordingly (Fig. 1D). Through the course of differentiation,
Celf1 mRNA dropped rapidly, which differs from previous report of Celf1
upregulation during terminal myocyte differentiation. The minor differ-
ence in media composition (the presence of dexamethasone in previous
studies) may have contributed to the discrepancy, dropping of Celf1
level during myoblast differentiation, however, agrees more with its
detrimental effect in myotube formation. CUG200 inhibited myoD
expression in both proliferating and differentiating cells, as previously
reported [17]. MyoG and Mef2c expression was inhibited by CUG200,
consistent with defective differentiation (Fig. 1C).
We next analyzed the impact of CUG-expansion on cell cycle control.
Because cell fusion creates heterogeneity in cell size, and at late stages of
myotube fusion the size of cells is not compatible with FACS, we limit
the analyses to early stages of culture. In proliferating undifferentiated
myoblasts, CUG200 led to signiﬁcantly less cells in G1 phase, suggesting
increased cell cycling (Fig. 1E). RNA toxicity is not known to be involved
in cell cycle regulation inDM,wehence set to study themechanismof it.
2.2. Overexpression of Celf1 inhibits myoblast cell cycle exit and impairs
differentiation
Compared to the established role of mutant DMPK 3′-UTR in
inhibiting myocyte differentiation, the role of Celf1 is unclear. Inmyotube area
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cells. (A) Myotube formationwas impaired in GFP-CUG200 transfected cells but intact in
ostaining. (B) GFP-CUG200 transfected cells had signiﬁcantly reduced fusion index (left)
oG, and Mef2c during the course of differentiation in GFP-CUG transfected cells. All assays
ted cells. (E) Increased cell cycling in GFP-CUG200 transfected myoblasts at ground state.
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program. To reconcile such discrepancies, we constructed a pMSCV-
based retroviral vector encoding a Flag-tagged Celf1, and used it to trans-
duce C2C12. Puromycin-resistant clones were pooled for differentiation
studies. Flag-tagged Celf1was only present in the pMSCV-Celf1Flag trans-
duced cells, which also showed an overall upregulation of Celf1 protein
(Fig. 2A). During differentiation, Celf1 overexpression led to a signiﬁcant
drop of myotube formation. MF20 positive staining was sporadic in
Celf1-overexpressing cultures (Fig. 2B). Consistently, quantiﬁcation
of myotube formation by fusion indices (5.2 ± 2.0% in Celf1Flag vs.
34.9 ± 11.7% in controls) and myotube areas (5.4 ± 3.0% in Celf1Flag
vs. 29.8 ± 12.7% in controls) suggests that overexpression of Celf1 se-
verely impair terminal myocyte differentiation (Fig. 2C). By analyzing
gene expression over the course of differentiation, we found that Celf1
overexpression led to an increase ofMyoDexpression in undifferentiated
myoblasts. This result is in line with previous reports where Celf1 andC
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Fig. 2. Overexpression of Celf1 inhibits myoblast differentiation. (A) Veriﬁcation of exoge-
nous Celf1Flag overexpression in C2C12 myoblasts by western blot. (B) Myotube formation
was impaired in Celf1Flag-overexpressing C2C12 cells. Myotubeswere visualized bymyosin
heavy chain (MF-20) immunostaining. (C) Celf1Flag overexpression led to reduced fusion
index and myotube areas. (D) Expression proﬁles of Celf1, and transcription factors MyoD,
MyoG, and Mef2c during the course of differentiation in Celf1Flag-overexpressing cells. All
assays by realtime RT-PCR. N N 3, p b 0.05.MyoD both drive p21 expression at the initiation step of differentiation
[9]. Despite increased MyoD expression, MyoG and Mef2c were both
inhibited, agreeing with defective myotube formation (Fig. 2D).
At single cell level, immunostaining of Flag and alpha myosin heavy
chain showed that the exogenous Celf1was chieﬂy located in thenucleus,
and such nuclei did not participate in myotube formation (Fig. 3A). Thus,
upregulation of Celf1 in the nucleus is not compatible with nascent
myotubes.
FACS cell cycle analyses showed that Celf1 overexpression led to de-
fective cell cycle exit during differentiation. 30.7% Celf1-overexpressing
myoblasts were in G1 phase at undifferentiated state, considerably
lower than control myoblasts in G1 (43.6%, Fig. 3B). This result largely
recapitulated the cell cycle defect caused by RNA toxicity (Fig. 1E).
Celf1 overexpression prevented exit from cell cycling at the initiation
stage of differentiation: there were 53.5% G1 cells in control myoblasts,
vs. 34.9% in Celf1-overexpressing myoblasts. These data suggest that
upregulation of Celf1 may be responsible for cell cycle exit defect in
CUG-expansion RNA toxicity.
Aberrant alternative splicing events are one of the chief characteristics
of DM. Here we studied if overexpression of Celf1 led to such changes in
myoblasts. Aberrant inclusion of exon 11 of Zasp, exon 7 ofMBNL1, exons
Zr4 and Zr5 of Z-TTN, exonMex5 ofM-TTN, and exon 11 of Bin1, among a
large number of aberrant alternative splicing events,waswell established
to be associated with DM1 [22,23]. By analyzing these exons, we found
that alternative splicing eventswere dynamic duringmyoblast differenti-
ation. For example, exon 11 of Zasp and exon Zr4 and Zr5 of Z-TTN
showed increased inclusion along the course of myotube formation.
Overexpression of Celf1 did not change the patterns of such dynamic
changes of the gene/exons under study (Supplemental Fig. S2). These
data suggest that aberrant alternative splicing does not mediate the
inhibiting role of Celf1 in myoblast differentiation.2.3. Knockdown of Celf1 promotes precocious myocyte differentiation
During embryogenesis and in adult tissues, Celf1 and other Celf family
members are abundantly expressed in neuroectoderm-derived proper-
ties and less in the muscular system. Despite the established role in
DM1, the requirement of Celf1 in myocyte differentiation is not
established. Thus, we used lentivirus-carried shRNA to knockdown Celf1
in C2C12 myoblasts. Puromycin (1 μg/ml) resistant clones transduced
with the lentiviral vectors were pooled for further experiments. Effective
reduction (~80%) of Celf1 was conﬁrmed by western blot (Fig. 4A).
Upon differentiation, myotube formation was accelerated in Celf1
knockdown cells. In our routine C2C12 differentiation experiments,
appearance of cell fusion starts after 3 days of induction in small numbers,
which prevailed in Celf1 knockdown cells (observation not shown). To
determine if Celf1 knockdown leads to precocious myocyte differentia-
tion, we collected samples for immunostaining at day 6, two days earlier
than in other experiments. Celf1 knockdown resulted in signiﬁcantly in-
creasedmyotube formation over control cultures (Fig. 4B). Fusion indices
and myotube areas were 45.0 ± 7.1% and 38.6 ± 7.2%, respectively, vs.
22.0 ± 1.9% and 16.1 ± 2.6% in control cells (Fig. 4C). By realtime
RT-PCR, we found that knockdown of Celf1 persisted throughout
the gradual dropping course of its expression pattern. The expression
of MyoD, MyoG and Mef2c showed signiﬁcant increases in Celf1 shRNA
cultures, supporting increased myocyte differentiation (Fig. 4D).
2.4. Knockdown of Celf1 partially rescues CUG-expansion induced myocyte
differentiation defects
Next, we asked if Celf1 contributes to the RNA toxicity effect in
inhibiting myocyte differentiation. Into the C2C12 cells stably transfected
withGFP-CUG200,we delivered Celf1 shRNAby lentiviral vectors. Double
resistant cells (G418 and puromycin)were selected and pooled for differ-
entiation studies. In the presence of Celf1 shRNA, the level of endogenous
BA Celf1Flag
DAPI Flag MergeMF20
Ctr Celf1Flag Ctr Celf1Flag
day 0 day 0 day 2 day 2
G1:43.6 G1:30.7 G1:53.5 G1:34.9
Fig. 3. Exogenous Celf1 accumulates in the nucleus and is excluded from myotubes. (A) Exogenous Celf1Flag was located primarily in the nucleus, which was excluded from myotubes.
Myotubeswere visualized byMF-20 immunostaining, while exogenous Celf1Flagwas visualized by V5-antibody staining. (B) Celf1 overexpression inhibited cell cycle exit duringmyocyte
differentiation. FACS was performed in undifferentiated myoblasts and day 2 differentiation culture.
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ing a scrambled shRNA (Fig. 5A).
The presence of Celf1 shRNA led to improvedmyocyte differentiation
in GFP-CUG200 cells. Compared to few multinucleate myotubes in GFP-
CUG200 cells expressing a scrambled shRNA, multinucleate myotubes
were evident in cells expressing Celf1 shRNA (Fig. 5B). Fusion indices
were improved from 2.3 ± 1.4% to 17.6 ± 1.1% by Celf1 shRNA. Consis-
tently, myotube areas were improved from 4.7 ± 3.1% to 12.7 ± 2.4%
(Fig. 5C). Celf1 knockdown in GFP-CUG200 cells did not completely re-
store the differentiation to what's seen in wildtype myoblasts (compare
Figs. 5B, C to 1A, B), suggesting that additional downstream factors
were involved in CUG-expansion-induced RNA toxicity on myogenesis.
Realtime RT-PCR assays of myoD, MyoG and Mef2c also support
that Celf1 shRNA partially rescued the differentiation defects in CUG-
expansion cells (Fig. 5E).
FACS cell cycle analyses showed that Celf1 shRNA corrected the
aberrantly increased cell cycling in CUG200 cells. There were 43.3% of
G1 cells in Celf1 shRNA/CUG200 cells, considerably greater than 31.5%
G1 in scrambled shRNA/CUG200 cells (Fig. 5D).
Lastly, we determined if Celf1 shRNA affected alternative splicing
events in RNA toxicity myoblasts. Compared to normal myoblast differ-
entiation (compare Supplemental Fig. S2 to Fig. 6), RNA toxicity resulted
in altered splicing patterns. For instance, exon 11 of Zasp showed re-
duced inclusion in RNA toxicity myotubes (day 6 of differentiation).
The exon 11 exclusion form of Bin1 showed increased expression in
normal myotubes (day 6 of differentiation), but aberrantly more in RNA
toxicitymyoblasts (days 0–1). In the presence of Celf1 shRNA, the altered
splicing patterns were not reversed (Fig. 6). The alternative splicing
dynamics were highly comparable during myoblast differentiation.
These data support that blockage of Celf1 upregulation has little to do
with alternative splicing regulation, which may explain the incomplete
rescue of differentiation in RNA toxicity cells.
3. Discussion
It's well established that DMPK 3′-UTR CUG-expansion is responsible
formyotonic dystrophy 1. CUG-expansionwas known to inhibit terminal
myocyte differentiation. Here, we show for the ﬁrst time that CUG-
expansion led to accelerated cell cycling which may partially explain
the defective differentiation. Introduction of Celf1 shRNA into CUG-
expansion cells partially rescued myocyte differentiation, by reversing
the cell cycle exit deﬁciency at myoblast level.
During normal development, DMPK and Celf1 are regulated inde-
pendently. While DMPK has a predominant expression in the muscles,
Celf1 is largely enriched in the neuroectoderm derivatives [24,25]. Theexpression patterns of Celf1 implies a non-obligatory role in muscle
differentiation, which is supported by the lack of muscle phenotype in
Celf1 knockout mice, such animals were chieﬂy defective in reproduc-
tion [26]. However, existing literature also indicates that Celf1 mediates
key events in myocyte differentiation. Here, we have determined the
function of Celf1 in normal myocyte differentiation using both loss
and gain of function experiments. When Celf1Flag is expressed in
C2C12 cells, it largely recapitulated the effect of CUG-expansion in
inhibiting myotube formation. The stably transfected Celf1Falg was
chieﬂy located in the nucleus, which is in line with previous reports
that cytoplasm Celf1 positively regulates myotube formation. But,
when endogenous Celf1 levels were knocked down by speciﬁc shRNAs,
myotube formation was promoted, resulting in a precocious differenti-
ation program. Our data herein support that in normal differentiation
conditions, Celf1 plays an inhibitory role in myogenesis. Also, Celf1
appears to be a powerful regulator of cell cycle. Overexpression of Celf1
signiﬁcantly increased the number of cycling cells in myoblasts and at
the initiation stage of differentiation. This essentially recapitulates the
cell cycle effect of CUG200, suggesting that Celf1 mediates the accelera-
tion of cell cycling in RNA toxicity myoblasts. It was reported that the
muscles fromDM1 patients had increased satellite cell number but with-
out proper terminal differentiation andmuscle regeneration, especially in
congenital cases [27,28]. The effect of Celf1 on cell cycle control may
explain such a bafﬂing phenomenon, and supporting that Celf1 upregula-
tion resulted from RNA toxicity may contribute to the pathogenesis of
congenital DM1.
It was recently reported that dominant negative CELF1 protein res-
cued splicing defects in a cell culture system and a DM1 mouse model
[29]. In this study, we have not observed signiﬁcant changes in DM1-
related alternative splicing events, when Celf1 was knockdown by
shRNAs. During myocyte differentiation, some DM1-related alternative
splicing events were dynamically regulated, but the presence of Celf1
shRNA did not alter the temporally regulated alternative splicing events.
Thus, we conclude that alternative splicing defects were not a major
factor in defective myocyte differentiation in DM1; instead, the cell
cycle exit defect may play a predominant role. As additional support of
this notion, a recent report of Celf1 knockout in the context of RNA toxic-
ity did not ﬁnd rescuing of defective alternative splicing: not only general
targets like Clcn-1 and Tnnt3 but also reported CELF1-speciﬁc targets
(Nrap and Fxr1h) remain misregulated by CUG-expanded RNA even in
the absence of CELF1 [30].
We also tried to answer if Celf1 upregulation is fully responsible for
CUG-expansion-led inhibition of myocyte differentiation. In contrast to
precocious myocyte differentiation resulted from Celf1 knockdown in
wildtype myoblasts, only partial rescue of differentiation was achieved
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Fig. 4. Celf1 knockdown leads to precocious C2C12 myocyte differentiation. (A) Western blot veriﬁcation of Celf1 knockdown by lentivirus-delivered shRNA. (B) Celf1 knockdown led to
increased myotube formation. (C) Celf1 knockdown increased the fusion index and myotube areas. (D) Expression proﬁles of Celf1, and transcription factors MyoD, MyoG, and Mef2c
during the course of differentiation in Celf1 knockdown cells. All assays by realtime RT-PCR. N N 3, p b 0.05.
1494 X. Peng et al. / Biochimica et Biophysica Acta 1852 (2015) 1490–1497in cells with CUG-expansion. CUG-expansion-induced cell cycling was
completely reversed by Celf1 knockdown. The rescue of cell cycle exit
defect, however, did not make the cells to differentiate to the degree
seen in wildtype cells. These data suggest that in myotonic dystrophy
myoblasts, upregulation of Celf1 was only partially responsible for the
defect in terminal differentiation. Additional pathological factors thatresulted from CUG-expansionmay also contribute to impaired differen-
tiation. In a recent study where Celf1 deﬁciency was evaluated for
correcting CUG-expansion RNA toxicity, the loss of CELF1 prevented de-
terioration of muscle function by the toxic RNA, and resulted in better
muscle histopathology [30]. Together, these data support that reduced
Celf1 levels in myoblasts may lead to better terminal skeletal muscle
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Fig. 6. Celf1 shRNA does not change the alternative splicing patterns during the differentiation ofmyoblasts harboring CUG-expansion. (A) RT-PCR analyzes of alternative splicing of Zasp,
MBNL1, Z-TTN,M-TTN and BIN1, in GFP-CUG200/Celf1 shRNA cells vs. GFP-CUG200/scrambled shRNA cells. The exonnumber under study is indicated. (B) Percentage of exon inclusion as
calculated from RT-PCRs.
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cially in congenital DM1 treatment. The newly developed CRISPR/Cas9
technology offers an excellent tool to achieve it. This strategy is partic-
ularly attractive as low efﬁciency gene correction in satellite cells can
lead to high phenotypic correction, as indicated in a recent report of
Duchenne muscular dystrophy gene editing [31]. This strategy may be
best employed in combination with other therapeutic strategies, such
as targeting defective alternative splicing.
4. Methods
4.1. Cell culture and differentiation
C2C12 mouse myoblasts were propagated in Dulbecco's modiﬁed
Eagle's medium, supplemented with 20% fetal bovine serum (FBS;
Atlanta Biologicals), 100 U/ml penicillin G, 100 μg/ml streptomycin
sulfate, and 2 mM L-glutamate. To induce myocyte differentiation and
myotube formation, the cells were grown in DMEM containing 2%
equine serum and 1 μM insulin (Sigma Aldrich). Sampleswere collected
on a serial of timepoints, includingdays 0 (in propagatingmedia), 2, 4, 6
and 8, except where otherwise speciﬁed, and were analyzed by immu-
nostaining, realtime RT-PCR, and FACS. Themediumwas replaced every
two days.
4.2. Vector construction and delivery
The GFP-CUG5 and GFP-CUG200 constructs were described previous-
ly [17,30]. Maxipreps of these plasmids were transfected into C2C12 cells
using Lipofectamine (Life Technologies). 2 days post-transfection, the
cells were selected with G418 (1 mg/ml) for 10 days, and the resistant
cells were analyzed in subsequent experiments as a pool.
pMSCV-Celf1Flag-Puro (thereafter referred to as Celf1Flag) was
constructed by inserting an EcoRI fragment containing Celf1Flag from
a donor plasmid pcDNA3-Celf1Flag (Tom Cooper, Baylor College of
Medicine) into pMSCV-Puro (Clontech).Maxipreps of the resulting con-
struct were used to prepare retroviral vectors using a packing cell line
293T Ecopack (Clontech). The retrovirus was next transduced into
C2C12 cells. 3 days post-transduction, the cellswere selectedwith puro-
mycin (2 μg/ml) for 5 days. Resistant cells were analyzed as a pool in
subsequent experiments.
pLKO.1 based Celf1 shRNA lentiviral vector was originally developed
by The RNAi Consortium (GE Healthcare, clone ID TRCN0000098511).
Scrambled control shRNA was obtained from the same source. For
virus production, 20 μg of shRNA-encoding lentiviral vector was
transfected along with 15 μg of packaging vector psPAX2 and 10 μg of
envelope vector pMD2.G (gifts fromDidier Trono, University of Geneva)
into a 150 mm dish of 293T cells, using calcium phosphate. Culture
supernatant containing lentiviral particles was collected 48 and 60 h
after transfection and combined. The pooled supernatant was cleared
of cell debris by centrifugation at 2000 rpm (1000 ×g) for 5 min.
0.5 ml of supernatant was used to infect a 60mmdish of C2C12 culture,
and resistant clones to puromycin (2 μg/ml) were pooled for subse-
quent analyzes.
4.3. Antibodies and immunoassays
Forwestern blotting, cell lysateswere size-fractionated by electropho-
resis in 8% or 10% SDS-polyacrylamide gels and transferred to nitrocellu-
lose membranes. Membranes were incubated in phosphate-buffered
saline, 3% bovine serum albumin, and 0.05% Tween-20 (Bio-Rad), and
then incubated overnight at 4 °C with the primary antibodies: mouse
monoclonal antibody to Celf1 (1:1000; Santa Cruz Biotechnology),
mouse antibody to Flag (1:2000; Santa Cruz Biotechnology), and goat an-
tibody to total actin (1:1000; Santa Cruz Biotechnology). Themembranes
were next incubated with horseradish peroxidase-conjugated secondary
antibodies to the appropriate IgG: anti-goat (1:1000, Santa CruzBiotechnology) and anti-mouse (1:2000, Pierce). Bound antibodies were
visualized with enhanced chemiluminescence reagents (Amersham
Biosciences).
For immunostaining, monolayer cultures were ﬁxed in 4% parafor-
maldehyde in PBS for 10min, followed by permeabilization in 0.1% Triton
X-100 in PBS for 30min at room temperature. The samples were next in-
cubated in blocking buffer (0.1% Triton X-100, 10% normal goat serum in
PBS) for 30 min at 37°. Primary antibody (MF-20, 1:100, Developmental
Hybridoma Bank; Flag, 1:100, Santa Cruz) incubation in blocking buffer
was carried out at 4° overnight. Secondary antibody (Texas red conjugat-
ed goat anti-mouse IgG, 1:500, Life Technologies) incubation in staining
buffer (0.1% Tween-20 in PBS) was 1 h at room temperature. Finally, im-
ages were visualized and captured with a Nikon ﬂuorescent microscope.
4.4. Realtime quantitative RT-PCR
Total RNA was extracted using TRIzol reagent (Invitrogen). RNA
(100 ng) was subjected to quantitative RT-PCR using the Taqman
One-Step RT-PCR Master Mix reagent (Applied Biosystems) and a
7700 Sequence Detector System (Applied Biosystems). Copy number
for each transcript is calculated relative to that of glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), as a constitutive control. Se-
quences of primers and probes are as the following: GAPDH (forward,
TGTGTCCGTCGTGGATCTGA; reverse, CCTGCTTCACCACCTTCTTGA;
probe, CCGCCTGGAGAAACCTGCCAAGTATG), MyoD (forward, CTGATG
GCATGATGGATTACAGC; reverse, GACACAGCCGCACTCTTCC; probe,
CGGCGGCAGAATGGCTACGACACC), MyoG (forward, GAGAGAAAGATG
GAGTCCAGAGAG; reverse, TCAGGAAGAGACTAGAACAGATGTG; probe,
ACACTTGTCCAGGTCAGGGCACTCA), and Mef2c (forward, TCCACTCCCC
CATTGGACT; reverse, TGCGCTTGACTGAAGGACTTT; probe, ACCAGACC
TTCGCCGGACGAAAG).
4.5. Alternative splicing analyses by RT-PCR
Total RNA was extracted using TRIzol reagent (Invitrogen). cDNA
was synthesized from 1 μg total RNA using the SuperScriptase III kit
(Invitrogen), and then ampliﬁed using gene/exon speciﬁc primers
[22,23]: Zasp (forward, GGAAGATGAGGCTGATGAGTGG; reverse, TGCT
GACAGTGGTAGTGCTCTTTC), MBNL1 (forward, GCTGCCCAATACCAGGTC
AAC; reverse, TGGTGGGAGAAATGCTGTATGC), Z-TTN (forward, TGTTGC
GACTGTCGTTGCTG; reverse, TCCACATGCGTAGGCTCTCTG), M-TTN (for-
ward, GTGTGAGTCGCTCCAGAAACG; reverse, CCACCACAGGACCATGTT
ATTTC), and BIN1 (forward, CACTATGAGTCTCTTCAAAC; reverse, GCAG
ATCCACGTTCATCTCC). PCR products were separated on 1% agarose gels
and the bands were quantiﬁed using the ImageJ software.
4.6. Fluorescence activated cell sorting
FACS was used to determine the cell cycle distribution of propagating
and early stage differentiated myoblasts. Brieﬂy, cells were harvested by
trypsinization and washed in PBS. Next, the samples were ﬁxed in
cold 70% ethanol for 30 min at 4°. After washing with PBS twice, the
sampleswere stainedwith propidium iodide (50 μg/ml in PBS containing
10 μg/ml RNase A) for 20min at room temperature. FACSwas performed
on an Acuri C6 ﬂow cytometer (Becton Dickinson), and the data were
analyzed using Flowjo software with the Dean–Jett–Fox model (Tree
Star).
4.7. Quantiﬁcation of staining and statistical analyzes
The fusion index of the cultures was calculated by dividing the total
number of nuclei inmyotubes (≥2 nuclei) by the total number of nuclei
counted. The totalmyotube areawas calculated as the percentage of the
total image area covered bymyotubes. At least 1000 nuclei were counted
in each analysis,which covered at least 3 randomly selected culture areas.
1497X. Peng et al. / Biochimica et Biophysica Acta 1852 (2015) 1490–1497Analysis of data was performed by Student's T tests in order to evaluate
differences between groups. p b 0.05 is considered signiﬁcant.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2015.04.010.
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